Gyros Protein Technologies and Cygnus Technologies to Develop Impurity Reagent Sets
The collaboration continues as the companies design bioprocess impurity reagent sets to detect residual HCP from HEK 293 cells.
Continuing their collaboration, Gyros Protein Technologies and Cygnus Technologies introduce a new HEK 293 host cell protein (HCP) immunoassay solution. The Cygnus HEK 293 HCP Assay Reagent Set for Gyrolab, a planned ready-to-use bioprocess impurity reagent, uses the Gyrolab platform, which will be developed by Cygnus.
The two companies’ previous collaboration yielded a successful launch of the ready-to-use Gyrolab CHO, HCP, and Escherichia coli HCP kits. Now, the companies are expanding the partnership to develop ready-to-use bioprocess impurity reagent sets.
The immunoassay solution is designed for use with the Gyrolab Bioaffy 1000HC Toolbox. It detects residual HCP from HEK 293 cells and is often used in viral vector production for cell and gene therapies as well as for manufacturing vaccines.
Source: Gyros Protein
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
